The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Open accessAbstract
The increasing dissemination of carbapenemases in Gram-negative bacteria has threatened the clinical usefulness of the β-lactam class of antimicrobials. A program was initiated to discover a new series of serine β-lactamase inhibitors containing a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials. Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases. Promising candidate molecules were synthesized and evaluated in biochemical and whole-cell assays. Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases. Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains. Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-negative bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Solving structures of protein complexes by molecular replacement with Phaser
McCoy, A. J. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906045975 · Cited by 1,595
Carbapenem resistance in Enterobacteriaceae: here is the storm!
Nordmann, P., Dortet, L., & Poirel, L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.003 · Cited by 1,038
Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 Å resolution
Strynadka, N. C. J., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K., & James, M. N. G. (1992) · Nature · doi:10.1038/359700a0 · Cited by 525
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
Flexible protein–ligand docking by global energy optimization in internal coordinates
Totrov, M., & Abagyan, R. (1997) · Proteins: Structure, Function, and Genetics · doi:10.1002/(sici)1097-0134(1997)1+<215::aid-prot29>3.0.co;2-q · Cited by 407
Self-citationActivity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.763030 · Cited by 154
Reversible inhibitors of penicillinases
Kiener, P. A., & Waley, S. G. (1978) · Biochemical Journal · doi:10.1042/bj1690197 · Cited by 139
Ness, S. R., Martin, R., Kindler, A. M., Paetzel, M., Gold, M. H., Jensen, S. E., Jones, J. B., & Strynadka, N. C. J. (2000) · Biochemistry · doi:10.1021/bi992505b · Cited by 133
Nanomolar Inhibitors of AmpC β-Lactamase
Morandi, F., Caselli, E., Morandi, S., Focia, P. J., Blázquez, J., Shoichet, B. K., & Prati, F. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0288338 · Cited by 130
Structural Milestones in the Reaction Pathway of an Amide Hydrolase
Beadle, B. M., Trehan, I., Focia, P. J., & Shoichet, B. K. (2002) · Structure · doi:10.1016/s0969-2126(02)00725-6 · Cited by 112
Structure-based design of a potent transition state analogue for TEM-1 β-lactamase
Strynadka, N. C. J., Martin, R., Jensen, S. E., Gold, M. H., & Jones, J. B. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-688 · Cited by 89
Shimizu‐Ibuka, A., Ishii, Y., Galleni, M., Ishiguro, M., Yamaguchi, K., Frère, J., Matsuzawa, H., & Sakai, H. (2003) · Biochemistry · doi:10.1021/bi0342822 · Cited by 82
Hydrolysis of Third-generation Cephalosporins by Class C β-Lactamases
Nukaga, M., Kumar, S., Nukaga, K., Pratt, R. F., & Knox, J. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312356200 · Cited by 68
A quick method for the determination of inhibition constants
Waley, S. G. (1982) · Biochemical Journal · doi:10.1042/bj2050631 · Cited by 61
Recognition and Resistance in TEM β-Lactamase
Wang, X., Minasov, G., Blázquez, J., Caselli, E., Prati, F., & Shoichet, B. K. (2003) · Biochemistry · doi:10.1021/bi034242y · Cited by 47
Watkins, R., & Bonomo, R. A. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.46 · Cited by 30
Cited by
β-Lactams and β-Lactamase Inhibitors: An Overview
Bush, K., & Bradford, P. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025247 · Cited by 1,412
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
The Science of Antibiotic Discovery
Lewis, K. (2020) · Cell · doi:10.1016/j.cell.2020.02.056 · Cited by 797
Metadata
- Authors
- Hecker, S. J., Reddy, K. R., Totrov, M., Hirst, G. C., Lomovskaya, O., Griffith, D. C., King, P., Tsivkovski, R., Sun, D., Sabet, M., Tarazi, Z., Clifton, M. C., Atkins, K., Raymond, A., Potts, K. T., Abendroth, J., Boyer, S. H., Loutit, J. S., Morgan, E. E., Durso, S., & Dudley, M. N.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-03-17
- Volume
- 58
- Issue
- 9
- Pages
- 3682-3692
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1968310807
- Cited by
- 422
- References
- 25
- Type
- other
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.